China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Sees Significant Growth in Short Interest

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a significant growth in short interest in May. As of May 15th, there was short interest totaling 6,460 shares, a growth of 97.9% from the April 30th total of 3,264 shares. Based on an average daily trading volume, of 23,541 shares, the short-interest ratio is presently 0.3 days. Currently, 0.7% of the company’s stock are sold short.

China SXT Pharmaceuticals Stock Performance

NASDAQ SXTC opened at $1.68 on Tuesday. China SXT Pharmaceuticals has a 52-week low of $1.25 and a 52-week high of $1,046.99. The company has a 50-day simple moving average of $1.78 and a 200 day simple moving average of $68.14.

Wall Street Analyst Weigh In

A number of research firms have weighed in on SXTC. Wall Street Zen raised shares of China SXT Pharmaceuticals to a “sell” rating in a research note on Saturday, February 7th. Weiss Ratings lowered shares of China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday, May 19th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Hedge Funds Weigh In On China SXT Pharmaceuticals

Several large investors have recently modified their holdings of the business. Virtu Financial LLC boosted its position in shares of China SXT Pharmaceuticals by 107.5% in the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after acquiring an additional 15,013 shares during the period. XTX Topco Ltd bought a new position in shares of China SXT Pharmaceuticals in the fourth quarter valued at approximately $36,000. Finally, Citadel Advisors LLC bought a new position in shares of China SXT Pharmaceuticals in the third quarter valued at approximately $78,000. Hedge funds and other institutional investors own 5.02% of the company’s stock.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.